The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Fruquintinib plus sintilimab in patients with either treatment-naive or previously first line treated metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multicenter, single-arm phase 2 study.
 
Dingwei Ye
No Relationships to Disclose
 
Xin Yao
No Relationships to Disclose
 
Zhisong He
No Relationships to Disclose
 
Hong Luo
No Relationships to Disclose
 
Guiling Li
No Relationships to Disclose
 
Jianming Guo
No Relationships to Disclose
 
Lei Diao
No Relationships to Disclose
 
Hua Xu
No Relationships to Disclose
 
Yu Fan
No Relationships to Disclose
 
Yuan Li
No Relationships to Disclose
 
Jiquan Fan
No Relationships to Disclose
 
Xiaoyi Hu
No Relationships to Disclose
 
Puhan Lu
Employment - HUTCHMED
 
Haiyan Shi
Employment - HUTCHMED
 
Panfeng Tan
Employment - HUTCHMED
 
Songhua Fan
Employment - HUTCHMED
 
Michael Shi
Employment - Transcenta
Leadership - Transcenta
Stock and Other Ownership Interests - Transcenta
Patents, Royalties, Other Intellectual Property - Multiple patents in oncology field at Novartis. Assign rights to Novartis
 
Weiguo Su
Employment - HUTCHMED
Leadership - HUTCHMED